Greenland Mines Secures Australian Patent for Klotho Gene Therapy Platform, Bolstering ALS Program

Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.

This patent grant is a significant milestone for Greenland Mines as it advances its biotech division, which focuses on innovative therapies for severe neuromuscular conditions. The Klotho protein, known for its anti-aging properties, has shown potential in neurodegenerative disease models. By securing patent protection in Australia, Greenland Mines establishes a competitive edge in the gene therapy landscape, particularly for ALS, a progressive neurodegenerative disease with limited treatment options. The patented technology covers key aspects of the therapeutic platform, including gene therapy constructs and delivery systems, which are critical for developing effective treatments.

The company’s KLTO-202 program is the primary indication for ALS, and this patent supports its continued development. ALS affects approximately 30,000 people in the United States alone, with a median survival of 2-5 years from diagnosis. Current treatments only modestly slow progression, highlighting the unmet medical need. The Klotho gene therapy approach aims to restore Klotho protein levels, which decline with age and are implicated in neurodegeneration. If successful, KLTO-202 could offer a novel disease-modifying therapy for ALS and potentially other neuromuscular disorders.

Greenland Mines operates with two divisions: Mining and Biotech. The mining division focuses on the Skaergaard Project in Greenland and the Sarfartoq rare earths project, while the biotech division advances Klotho-based therapies. The company’s strategy is to build a multi-asset platform with exposure to rare earth magnet materials, precious metals, and biotech opportunities. The patent news underscores the company’s commitment to its biotech pipeline, which could diversify revenue streams beyond mining.

For more details, the full press release is available at https://nnw.fm/PVbbH. The latest news and updates relating to GRML can be found in the company’s newsroom at https://ibn.fm/GRML.

This patent grant represents a key step for Greenland Mines in protecting its gene therapy platform and advancing KLTO-202 toward clinical development. With a strong IP position, the company is better positioned to pursue partnerships and funding opportunities to accelerate the program. Investors and stakeholders will be watching for further developments as the company progresses its biotech initiatives.